Clinical-stage biotechnology company developing next-generation immunomodulatory and Fc-based therapies for chronic inflammatory and autoimmune diseases
Clinical-stage biotechnology company developing next-generation immunomodulatory and Fc-based therapies for chronic inflammatory and autoimmune diseases. Its approach aims to restore immune homeostasis and treat underlying disease without broadly suppressing immune function. Lead asset NVG-2089 is in Phase 2 development for chronic inflammatory demyelinating polyneuropathy (CIDP).